9/5/2023
QIA is part of a consortium of investors in a Series C financing round.
The financing will support a study for Von Willebrand disease, a lifelong bleeding disorder.
The investment aligns with QIA’s ambition to support companies that can address major unmet medical needs.
Doha, September 5, 2023 – Qatar Investment Authority (QIA) has invested in Star Therapeutics, a biotechnology company focused on developing life-changing therapies for rare diseases. The financing was led by a consortium of investors including QIA and has raised $90 million in Series C financing for the company.
This financing will support Vega Therapeutics - a Star portfolio company focused on underserved blood disorders - progress in the clinical advancement of VGA039, a first-in-class antibody currently being evaluated in a Phase 1a/1b study for Von Willebrand disease, a lifelong bleeding disorder.
Proceeds will also be used to continue Star’s approach as an innovation engine to generate additional biotech companies focused on discovering and advancing novel antibody therapies, each targeting multiple diseases.
This investment aligns with QIA’s ambition to support companies that can address major unmet medical needs and develop innovative new treatments and curative therapies for people impacted by these conditions across the world.